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Abstract
Background: Pompe disease is a rare, progressive, metabolic disease, and the first treatable inheritable muscle
disorder. Enzyme replacement therapy (ERT) with alglucosidase alfa is disease specific and the only medicinal
product authorized for the treatment of Pompe disease. Costs of ERT are very high as for most orphan drugs. This
study investigates the cost-effectiveness of ERT compared to supportive treatment in adult patients with Pompe
disease.
Methods: Survival probabilities were estimated from an international observational dataset (n = 283) using a time-
dependent Cox model. Quality of life was estimated on a Dutch observational dataset using a previously developed
conceptual model which links clinical factors to quality of life. Costs included costs of ERT, costs of drug administration
and other healthcare costs. Cost-effectiveness was estimated using a patient-level simulation model (n = 90), synthesising
the information from underlying models for survival, quality of life and costs. The cost-effectiveness model estimated the
(difference in) lifetime effects and costs for both treatments. Two scenarios were modelled: (1) a worse case scenario with
no extrapolation of the survival gain due to ERT beyond the observed period (i.e. from 10 years onwards); and (2) a best
case scenario with lifetime extrapolation of the survival gain due to ERT. Effects were expressed in (quality adjusted) life
years (QALYs). Costs were discounted at 4.0% and effects at 1.5%.
Results: Substantial increases in survival were estimated – discounted incremental life years of ERT ranged from 1.9 years
to 5.4 years in the scenarios without and with extrapolation of survival gains beyond the observed period. Quality of life
was also significantly better for patients receiving ERT. Incremental costs were considerable and primarily consisted of the
costs of ERT. Incremental costs per QALY were €3.2 million for scenario 1 and €1.8 million for scenario 2.
Conclusions: The availability of extended, prospectively collected, longitudinal observational data on the most important
input parameters required to construct a cost-effectiveness model is quite exceptional for orphan diseases. The cost-
effectiveness model showed substantial survival gains from ERT. Despite these substantial gains, ERT was not cost-
effective in the treatment of adult Pompe disease because of the high cost of treatment.
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Background
Pompe disease (or glycogenosis type II) is a rare inherit-
able muscle disease that also belongs to the glycogen
and lysosomal storage disorders. It is caused by a defi-
ciency of the enzyme acid α-glucosidase [1]. The disease
has a continuous clinical spectrum of phenotypes, with
the progressive, classic-infantile form at the severe end
of the spectrum and the late-onset form at the least
severe end. In adult patients, the disease particularly
affects skeletal muscle and respiratory function, and
patients eventually become wheelchair bound and venti-
lator dependent [1–3]. The frequency of adult Pompe
disease is estimated to be 1 per 57:000 people [4].
Compared to the general population, adults with Pompe
disease experience a reduced life expectancy and quality
of life [5–7].
Enzyme replacement therapy (ERT) with alglucosidase
alfa (Myozyme®, Genzyme corp.) has been developed as
a disease specific treatment for Pompe disease. Before
ERT became available in 2006, patients received
supportive treatment (ST) only, consisting of respiratory
support, ambulatory support, physiotherapy and/or diet-
ary treatment [8]. In adult patients with Pompe disease,
ERT has been shown to improve muscle strength,
respiratory function and quality of life [9, 10]. Further-
more, it leads to a significant improvement in survival in
both infants and adults [11–13]. Like other treatments for
rare diseases, ERT is very expensive. Costs-effectiveness is
one of the criteria on which reimbursement decisions are
based. In cost-effectiveness studies, the ratio of incremen-
tal costs and incremental effects of a new treatment versus
a comparator is calculated. In this study, we examined, for
the Dutch situation, the cost-effectiveness of ERT com-
pared to ST in adult patients with Pompe disease. Consid-
ering the costs associated with ERT, the treatment is not
expected to have a favourable cost-effectiveness ratio. Still,
it is necessary to conduct economic evaluations, as it pro-
vides policy makers with an instrument to engage in price
negotiations with drug manufacturers and a comparison
of the cost-effectiveness of treatments with other orphan
drugs can contribute to the debate on whether or not, for
orphan drugs, we may need reimbursement decisions that
explicitly incorporate broader societal preferences.
Methods
The Dutch health economic guidelines were followed in
this cost-effectiveness study. A patient-level simulation
model was developed to assess cost-effectiveness of ERT
for adult patients (i.e. 18 years or older) with Pompe
disease. In such a model, outcomes are calculated for in-
dividual patients and then the average is taken over the
total patient population included [14]. The model com-
pared two treatments: supportive treatment (ST) and
enzyme replacement therapy with supportive treatment
(ERT). The model was composed of three main compo-
nents, i.e. survival, quality of life, and costs, which were
modelled on the basis of an individual patient’s charac-
teristics for both treatments.
Survival
Survival probabilities were derived from an international
dataset with observational data of patients with Pompe
disease (the International Pompe Association (IPA)/
Erasmus MC Pompe Survey; n = 283), which started to
collect data in 2002, 4 years before ERT received market
authorization. This database was previously used to esti-
mate survival of adult patients with and without ERT by
means of a time-dependent Cox regression model using
wheelchair use, ventilator support and treatment as
predictors [13]. For the cost-effectiveness model, this
survival model was adapted to estimate the baseline
hazard for both treatments using the same dataset. This
method provides a life table for both treatments (esti-
mated cumulative survival probabilities are provided in
Table S1 (see Additional file 1). To make optimal use of
all available data, patients contribute data to the survival
estimates of both treatments; i.e. patients that received
ERT also contributed data to estimate the survival in the
ST group before they received ERT. For both treatments,
the mean observed follow-up was approximately 3.5 years
with a maximum total follow-up for ST of 8.9 years and
for ERT of 8.4 years.
Because the survival after the observed period is
uncertain, two scenarios were modelled. In scenario 1, a
conservative approach was used, assuming no effects of
ERT on survival after the observed period. Hence, from
year 10 onwards, the survival probabilities estimated for
ST at 9 years were kept constant and applied to both
treatments in this scenario. This scenario presents a
worse case scenario, as no further improvements in sur-
vival due to ERT were assumed beyond the observed
survival gains, resulting in the lower boundary of sur-
vival gains due to ERT. In scenario 2, the effect of ERT
on survival was extrapolated beyond the observation
period, by carrying forward the estimated treatment-
specific survival probabilities of year nine (see Additional
file 1: Table S1) for both treatments. To adjust for an
increasing risk of mortality with increasing age, the
estimated probabilities were replaced by age-based mor-
tality rates for the general Dutch population when these
were larger than disease-specific mortality rates. Mortal-
ity rates for the Dutch population were derived from
Statistics Netherlands [15].
Quality of life
A previously developed conceptual model for adult
Pompe disease, connecting clinical parameters with
quality of life [16] was used to obtain estimates for an
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individual patient’s quality of life. The conceptual model
describes the relations between enzyme activity, muscle
strength, respiratory function, fatigue, level of handicap,
general health perceptions, and utility. The quality of life
model in the cost-effectiveness model resembled the
conceptual model for adult Pompe disease, except that
the estimates from the conceptual model were recalcu-
lated using a model specification that included ERT as a
covariate, in order to model treatment effects. The other
covariates in the quality of life model were age, disease
duration and enzyme activity. Using the regression esti-
mates from the conceptual model in combination with
patient characteristics (age, disease duration, enzyme
activity and treatment), the patient’s muscle strength and
respiratory function were estimated. The estimated
values for muscle strength and respiratory function were
used as input values (next to the patient characteristics)
in the regression model for the subsequent level in the
conceptual model, i.e. fatigue. Fatigue was used, in com-
bination with muscle strength, respiratory function and
patient characteristics, to estimate the next level in the
conceptual model, namely handicap level. Handicap and
patient characteristics were used in turn to estimate
health perceptions. The final level in the conceptual
model, i.e. quality of life, was estimated on the basis of
the patient’s estimated health perceptions, and the pa-
tient characteristics (age, disease duration, enzyme activ-
ity and treatment). Regression estimates for the quality
of life model were based on a Dutch dataset (n = 82),
consisting of a sample of all Dutch patients being moni-
tored (both treated and untreated) by the national refer-
ence center for Pompe disease (Erasmus MC, University
Medical Center, Rotterdam, the Netherlands). Regression
estimates are provided in Table S2 (see Additional file 1).
The ERT covariate in the quality of life model showed a
significant positive effect on utility: utilities for ERT were
0.028 points higher than for ST (p = 0.008, (see Additional
file 1: Table S2)).
Quality of life was expressed in utilities, which repre-
sents the value of a patients’ quality of life on a scale
anchored at 1 (perfect health) and 0 (death). Utilities
were derived from the EQ-5D questionnaire [17]. Dutch
tariffs were used to calculate utilities [18].
Costs
Costs were calculated from the societal perspective and
expressed in 2014 euros. Several costs components were
included in the cost-effectiveness model.
ERT costs were based on patients’ weights; dosage was
20 mg/kg body weight every 2 weeks. Patients’ weights
were estimated using a random effects model, including
age and gender as explanatory variables. The estimates
of bodyweight were based on a dataset from the hospital
pharmacy on the Dutch patients being treated with ERT
at Erasmus MC, University Medical Center, Rotterdam,
the Netherlands (n = 84). Patients’ weights were multi-
plied by the list price of medication – ERT costs per
kilogram bodyweight were €5788 per year. Because of
organizational efficiency in the hospital pharmacy,
spillage was very low; therefore, no costs of spillage
were included.
Cost of drug administration were based on biweekly
infusions. Infusions were provided outside the hospital
(mostly at home) for 79% of patients. Based on bottom-up
costing research, these costs of drug administration out-
side the hospital were estimated to be €433; compared to
€507 for in-hospital drug administration. A weighted aver-
age was used to calculate costs of drug administration.
Other healthcare costs were retrieved from health eco-
nomic questionnaires [6] among Dutch patients (n = 87)
at Erasmus MC, University Medical Center, Rotterdam,
the Netherlands. These costs related to hospitalizations,
outpatient visits, GP visits, paramedical care, home care,
diagnostic procedures and medical aids were included in
the analyses. For valuation, reference prices were used
from the Dutch costing manual [19]. Costs for informal
care were added to the healthcare costs and valued using
the opportunity cost method [20]. Productivity costs were
retrieved from self-reported data on absence from paid
work and reduced efficiency at work and were calculated
using the friction cost method [21]. Both healthcare
utilization costs (including informal care) and productivity
costs were estimated using two GLM models (one model
for ST and one model for ERT), with age, gender, disease
duration as explanatory variables (regression estimates are
provided in Table S3 (see Additional file 1).
Cost-effectiveness
Effects were expressed in life years gained and quality
adjusted life years (QALYs) gained. QALYs are calculated
as the number of life years gained corrected for the qual-
ity of life (i.e. utility) during these life years. Incremental
cost-effectiveness ratios (ICERs) were presented as both
incremental costs per life year gained and incremental
costs per QALY gained. Probabilistic sensitivity analysis
(PSA) was performed and the 95% confidence intervals
(CI) were derived from the 2.5th and 97.5th percentiles
of the PSA iterations.
Model settings
A double-loop model was used to represent patient het-
erogeneity and parameter uncertainty [22]. The double-
loop model consisted of 30 simulated populations of 90
bootstrapped patients (equal to the number of patients
for which data for all patient characteristics that were
used as input parameters in the cost-effectiveness model
were available) and 1000 Monte Carlo simulations (see
Additional file 1: Figure S1). The inner loop represented
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patient heterogeneity, the outer loop represented param-
eter uncertainty. Firstly, in the outer loop, values from
the distributions of all regression coefficients in the
models of survival, quality of life and cost models were
drawn. These values were kept constant for a sample of
90 bootstrapped patients in the inner loop. Using the
information on these 90 patients, individual estimates
for survival, quality of life and costs were made, for both
ST and ERT, and averaged over this population of 90
patients. This process was repeated 30 times in the inner
loop. Then, this entire process was repeated 1000 times
in the outer loop.
A lifetime time horizon was used in the base case ana-
lyses. Patients in the ERT (ST) group were modelled to
receive ERT (ST) until death; i.e. in the model patients
did not switch treatments. Effects were discounted using
a discount rate of 1.5%; costs were discounted at 4.0%,
as recommended by the Dutch pharmacoeconomic
guidelines [23]. Discounting is done to adjust for time
preferences; the further the gains and losses occur in the
future the less weight they get.
The cost-effectiveness model was programmed in
Microsoft Excel 2013 (Microsoft, 2013). Survival analyses
were performed using R [24]. Regression models for qual-
ity of life and costs were estimated in Stata version 14.1
(StataCorp, 2015). The analyses were performed on
patient level data until the year 2011.
Sensitivity analyses
Two types of structural uncertainty were assessed by
means of one-way sensitivity analyses. Firstly, a simpler
regression model was used to estimate survival: survival
was estimated using treatment as the only explanatory
variable. Secondly, the influence of the time horizon on
the ICER was assessed by using shorter time horizons
for the cost-effectiveness analyses (i.e. time horizons of
5 years and 15 years).
Next to assessing the structural uncertainty of the model,
the influence of specific input parameters on the outcomes
was assessed in one-way sensitivity analyses. Price of medi-
cation was reduced by 20% to investigate the influence of
the price of ERT on the ICER. Furthermore, analyses were
run using a discount rate of 0% for both costs and effects.
To test the influence of the utility gain on the ICER, utility
gains were set to zero and to 0.1 in two separate sensitivity
analyses. Similarly, increases in healthcare costs other than
costs of ERT were set to zero to test for the influence of
those costs on the ICER. Finally, a sensitivity analysis was
performed in which the lifetable was used until year 8 (i.e.
the point at which for at least 25% of the initial population
data were still available for analysis), and this value was
carried forward to later years. This sensitivity analyses was
performed to assess the influence of the small sample size
for the survival model in the ninth year.
Results
Patient population
Table 1 shows the baseline (i.e. first visit in the database)
patient characteristics for the patients included in the
cost-effectiveness model. The cost-effectiveness model
included data of adult patients in the age range of 23 to
75 years at first visit.
Survival
Survival probabilities for ERT were higher than for ST
(see Additional file 1: Table S1). The resulting survival
curves for ST and ERT are given in Fig. 1. In both
scenarios, survival increased substantially due to ERT. In
scenario 1, a worse case scenario with no extrapolation
of survival gains after the observed period, undiscounted
life expectancy was approximately 2.6 years longer for
ERT patients than for ST patients (i.e. the difference
between the blue and dashed line), using a lifetime time
horizon. Table 2 shows that incremental life years were
1.9 years when a 1.5% discount rate on effects was ap-
plied. Survival gains were even larger in scenario 2; life
expectancy increased with 8.2 years without discounting,
and 5.4 years when discounting was applied.
Quality of life
The average difference in discounted utilities found in the
cost-effectiveness model was 0.03 (Table 2). Estimated
Table 1 Baseline characteristics of Pompe patients included in the cost-effectiveness analyses (n = 90)
Mean Median Range
Age at first visit 49.1 years 50.0 years 23.0–75.0 years
Disease duration (since diagnosis) 7.7 years 4.3 years 0.0–27.6 years
Female 48%
Residual Enzyme activity (in fibroblasts) 12.0% 12.0% 0.5–19.9%
Wheelchair use 31%
Ventilation use 27%
Period at risk in ST survival analyses 3.5 years 3.5 years 0.0–8.9 years
Period at risk in ERT survival analyses 3.4 years 3.7 years 0.2–8.4 years
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utilities for both treatments decline over time, due to
worsening clinical parameters which translate into utility
decreases through the conceptual quality of life model.
Discounted QALYs were 2.0 (scenario 1) and 4.3 (scenario
2) higher for ERT than for ST over a lifetime period.
Costs and cost-effectiveness
Undiscounted annual treatment costs for an average
weight patient was €450,000. Table 2 further shows costs
for both treatments. In scenario 1, discounted lifetime
incremental costs were approximately €6.5 million, con-
sisting mainly (96.7%) of drug costs. Incremental costs
for scenario 2 were €7.6 million, because patients lived
longer and received ERT for a longer period of time.
ERT did not reduce other healthcare costs, because ERT
improves survival and during these additional years of
life patients still need routine monitoring and other
forms of healthcare and informal care.
For scenario 1, the ICER was estimated at €3.4 million
per life year gained and €3.2 per incremental QALY. The
ICERs for scenario 2 were lower; €1.4 million per life
year gained and €1.8 million per incremental QALY.
A cost-effectiveness plane visualizes the variation in
incremental effects and incremental costs, as it presents
the results for each of the outer loop iterations. The
cost-effectiveness plane in Fig. 2 shows the outcomes of
the 1000 model iterations for both scenarios (i.e. each
dot represents one outer loop, given the 30 simulated
heterogeneous populations of 90 patients that were
drawn in the inner loop). Uncertainty is primarily present
concerning the difference in effects, especially when
extrapolating survival gains in scenario 2. Uncertainty
surrounding survival gains is the underlying determinant
of the variation in PSA outcomes. The cost-effectiveness
acceptability curve in Fig. 3 shows the percentage of simu-
lations with a cost-effective outcome under a pre-specified
cost-effectiveness threshold. Using a cost-effectiveness
threshold of either €50,000 or €80,000/QALY (the upper
limit in the Netherlands, depending on the severity of the
disease), 0% of iterations would be considered cost-
effective in either of the scenarios. When a threshold of
€4.7 million per QALY is used 95% of iterations would be
considered cost-effective in scenario 1, for scenario 2 this
occurs at a threshold of €3.5 million per QALY.
Sensitivity analyses
Table 3 shows the outcomes of the various sensitivity
analyses. The effect of using a simpler model specifica-
tion for survival, i.e. using treatment as the only covari-
ate, on the ICER was limited. Changing the time horizon
had the largest influence on the ICER. The ICER was
higher with shorter time horizons; using a 5-year
horizon the ICER was €15.6 million per life year gained
(€7.0 million per QALY) and using a 15-year horizon the
ICER was 3.9 million per life year gained (€3.6 million
per QALY). Both incremental costs and effects were
lower for the shorter time horizons than in the base
case. The ICER increased mainly because of the lower
survival gains. In the analyses with the 15-year time
horizon discounted incremental life years were estimated
to be 1.2 years. Discounted incremental life years were
0.1 years in the analyses with a 5-year time horizon; this
survival gain was exclusively based on observed data.
This is consistent with Fig. 1 and Table S1 (see
Additional file 1), which showed that gains in survival
increased after 5 years.
When an ERT-price reduction of 20% was modelled,
incremental costs decreased to €5.2 million. The ICER
decreased to €2.6 million per life year gained and €2.5
million per QALY gained. Without discounting, the
ICER was €4.3 million per life year gained and €4.2
million per QALY. Discounting affected both costs and
effects, but due to the differential discount rates it
reduced the net present value of costs more than the net
present value of effects. Disregarding utility gains
reduced the incremental QALYs, but the impact on the
ICER was limited. When the improvement in quality of
life due to ERT was kept constant at 0.1 instead of 0.03
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as derived from the quality of life model, incremental
costs per QALY was €2.2 million. Excluding differences
in other healthcare costs, or using survival data until
year 8, had virtually no effect on the ICER. The sensitiv-
ity analyses for scenario 2 showed similar findings.
Discussion
This study assessed the cost-effectiveness of ERT versus
ST in adult patients with Pompe disease from a societal
perspective. Survival increased considerably because of
ERT. Using a lifetime time horizon the model showed
that discounted life expectancy increased by up to
5.4 years when survival was extrapolated (scenario 2).
Furthermore, ERT had a positive effect on quality of life
of patients. However, the cost-effectiveness ratio is
primarily determined by the costs of ERT. In the best
scenario, this resulted in an incremental cost per life
year gained of €1.4 million and an incremental cost per
QALY ratio of €1.8 million.
The results of our analyses are in line with other stud-
ies that show that orphan drugs are usually not cost-
effective under common cost-effectiveness thresholds,
primarily because of their high prices. In comparison,
ERT in Fabry disease for instance was associated with an
incremental cost of €3.3 million per QALY gained [25].
When compared to various expensive cancer therap-
ies, the effectiveness of ERT in Pompe disease is much
larger in terms of absolute life years gained. For
example, nivolumab increased survival of lung cancer
patients by 0.61 years when compared to docetaxel [26]
and pertuzumab increased survival of breast cancer
patients by 1.4 years in comparison to trastuzumab/do-
cetaxel [27]. This study has shown an increase in life
expectancy due to ERT of 5.4 years (in scenario 2). Des-
pite these larger effects, the cost-effectiveness ratio is
less favourable for ERT in Pompe disease (nivolumab:
€134,000 per QALY; pertuzumab: €148,824 per QALY)
[26, 27]. As such, the study particularly shows the effect
of the high price of ERT on the ICER. Medication costs
of ERT are further increased because of the relatively
high dose needed to reach muscle tissue; research has
shown that a dosage of at least 20 mg/kg is needed to be
effective [1, 11, 28].
In this study the list price of alguclosidase alfa was used.
In March 2016, the market exclusivity period for alglucosi-
dase alfa ended in Europe (and the manufacturer subse-
quently withdrew the product from the EU register of
designated orphan medicinal products). This enabled other
companies to enter the market with generic (cheaper)
versions of the therapy. To date, no such alternatives exist.
-
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Strengths and limitations
Research in orphan drugs in general may be hampered
by small patient numbers and lack of data and this also
holds for cost-effectiveness studies [29, 30]. However, in
the current study we had access to a large international
longitudinal dataset with observational data to estimate
survival. In addition, quality of life and costs were
estimated by using an extensive dataset containing long-
term follow-up on both ST and ERT. The availability of
data for both ST and ERT was essential to perform an ad-
equate cost-effectiveness study. When survival is affected,
using an international dataset might be the only option to
gather enough data to estimate cost-effectiveness. The
availability of the relatively large amount of data for the
various components in a cost-effectiveness study, i.e.
survival, quality of life and costs, is exceptional, given the
rarity of the disease.
Pharmacoeconomic guidelines prescribe the use of a
time horizon that captures all benefits and costs of a
treatment. In this respect, a lifetime horizon was most
appropriate for modelling the cost-effectiveness in adult
Pompe disease. If the time horizon is longer than the
follow-up of the data (as was the case in this study),
observed (survival) data need to be extrapolated. Be-
cause extrapolation (particularly of effects) is associated
with uncertainty, especially when the time horizon is
lifetime, we present two different scenarios. In scenario
1, in which we only include the survival gains in the
observed period, we assume no gains in survival beyond
the observed period, as a worse case scenario. In
scenario 2, we extrapolated survival gains beyond the
observed period. ICER estimates ranged from €3.2 mil-
lion (scenario 1) to €1.8 million per QALY (scenario 2).
Although this is a broad range in absolute terms, it also
showed that the ICER is high even when the largest
expected survival gain is modelled.
The number of patients in the dataset used to model
survival was not sufficient to incorporate other explana-
tory variables in the Cox proportional hazard model
than wheelchair use and ventilator support. Therefore,
Table 3 Results one-way sensitivity analyses
Incr. LY Incr. QALY Incr. Costs Cost/LY Cost/QALY
Scenario 1: No extrapolation of survival gains
Base Case 2.03 2.13 € 6,486,112 € 3,195,040 € 3,050,814
Structural uncertainty
Survival: ERT as only covariate 2.15 2.08 € 5,780,738 € 2,692,018 € 2,772,920
5 year time horizon 0.13 0.29 € 2,043,440 € 15,558,121 € 6,958,412
15 year time horizon 1.19 1.31 € 4,681,908 € 3,944,770 € 3,567,548
Input values
Medication costs 20% reduced 2.03 2.13 € 5,234,010 € 2,578,258 € 2,461,874
Discount rates 0% 2.61 2.69 € 11,186,321 € 4,287,545 € 4,162,930
No utility gain 2.03 1.26 € 6,486,112 € 3,195,040 € 5,138,186
Utility gain of 0.10 2.03 3.03 € 6,486,112 € 3,195,040 € 2,139,947
No difference in healthcare costs except for cost of ERT 2.03 2.13 € 6,418,842 € 3,161,903 € 3,019,173
Survival: last value carried forward from year 8 onwards 1.98 2.08 € 6,387,051 € 3,231,592 € 3,073,535
Scenario 2: Extrapolated survival gains
Base Case 5.67 4.38 € 7,564,035 € 1,334,081 € 1,726,636
Structural uncertainty
Survival: ERT as only covariate 5.44 4.14 € 6,749,881 € 1,241,847 € 1,629,079
5 year time horizon 0.13 0.29 € 2,043,440 € 15,558,121 € 6,958,412
15 year time horizon 1.59 1.58 € 4,836,654 € 3,047,385 € 3,053,857
Input values
Medication costs 20% reduced 5.67 4.38 € 6,121,967 € 1,079,741 € 1,397,456
Discount rates 0% 8.22 6.12 € 14,480,052 € 1,761,281 € 2,367,014
No utility gain 5.67 3.34 € 7,564,035 € 1,334,081 € 2,265,117
Utility gain of 0.10 5.67 5.47 € 7,564,035 € 1,334,081 € 1,382,324
No difference in healthcare costs except for cost of ERT 5.67 4.38 € 7,390,957 € 1,303,555 € 1,687,127
Survival: last value carried forward from year 8 onwards 5,65 4.36 € 7,478,037 € 1,323,777 € 1,716,538
Base case results differ somewhat from Table 2 as sensitivity analyses were performed using deterministic analyses
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the effect of age on disease-specific survival could not be
modelled. Hence, the effect of age on survival was limited
to modelling of background mortality. A final limitation
with regard to modelling survival was that beyond the
observed period, the last-observed value from the life
tables was carried forward. Actual survival was observed
for a period up to nine years; estimated 9-year survival
probabilities were extrapolated beyond this period. Sensi-
tivity analyses showed that results were not affected when
the values of year 8 were carried forward instead of the
values for year 9. Ideally, a parametric survival function
would have been fitted to the observed data, but this was
not possible with the available dataset in which the same
patients were on ST for a certain period after which they
could switch to ERT. Information on long-term effects of
ERT in Pompe disease with respect to survival is needed
to assess the plausibility of the two scenarios.
The data used in this study were derived from observa-
tional studies. Observational studies can suffer from vari-
ous types of biases, such as performance bias, selection
bias and loss to follow-up [31, 32]. Performance bias
occurs when patients and clinicians are not blinded, and
can lead to an overestimation of treatment effects [32].
Selection bias can lead to differences in patient character-
istics between groups, which can obscure the determin-
ation of treatment effects; i.e. when patients have different
prognosis at start of treatment it cannot be established
whether effects are caused by the treatment or by the
initial differences in prognosis of patients [31]. Perhaps
patients are in different stages of the disease when treated
with ST or ERT. In our study, the impact of selection bias
on the estimated survival was reduced because in the
time-dependent Cox proportional hazard model, the
patients that received ERT also contributed survival data
to the ST group. Furthermore, by including age, gender
and disease duration in the quality of life and costs regres-
sion models, and by using wheelchair and ventilator use in
the survival model, we tried to correct for differences in
patient characteristics as far as the data allowed. Loss to
follow-up was limited for the Dutch patients in the study,
because in the Netherlands all patients with Pompe
disease are referred to the single expert centre at the
Erasmus MC. Erasmus MC uses an extensive standardized
follow-up protocol for all patients, which are either treated
at the Erasmus MC, or elsewhere under supervision of
Erasmus MC. Furthermore, loss to follow-up is reduced as
patients are obligated to complete specific measurements
and questionnaires. Hence, this study did capture the vast
majority of the total Dutch population (>80%) of adult
patients with Pompe disease.
Policy implications
Evidence-based policy making and health technology
assessment (HTA) may assist policy makers to effectively
prioritise health interventions and make consistent deci-
sions. This study showed that despite significant survival
gains, the treatment for this very rare disease will never
be titled cost-effective at the current price-level of the
drug. Considerable price reductions will be needed to
improve the cost-effectiveness ratio of this effective
therapy. The exact causes of the high price for orphan
drugs remain unclear, because a breakdown of this price
in different components is not publicly disclosed. It
could be due to several factors, such as high R&D costs,
high production costs (particularly for complex manu-
facturing processes like the production of recombinant
human alglucosidase alfa), lack of competition and the
high perceived value of the drug. Transparency about
price setting of orphan drugs is needed to justify their
high prices, especially given the evidence on high gross
profit margins on orphan drugs compared to other drugs
[33, 34]. However, even if payers manage to negotiate
price reductions, the European system of international
reference pricing, in combination with parallel trade
being legal, jeopardizes transparency about prices.
Unfavourable cost-effectiveness ratios do not only
apply to the treatment of Pompe disease, but have been
recognized for orphan drugs in general. To address this
challenge, common collaboration between national
healthcare authorities may support to increase negoti-
ation power and reduce drug prices. Currently, the
governments of the Netherlands, Belgium, Luxembourg
and Austria collaborate in this respect [35], but this
coalition preferably needs to be extended to other coun-
tries to improve the result of the negotiations. Transpar-
ency in price setting is a key issue in successful price
negotiations, especially to safeguard payers from high
prices for orphan drugs that result from misuse of
orphan drug legislation (e.g. price increases for existing
drugs after getting orphan designation; salami slicing)
rather than (possible) acceptable reasons. It should be
noted that treatment with alglucosidase alfa for Pompe
disease is disease specific and cannot be used for other
diseases. What could also contribute to reducing the
ICER is to better target the therapy to those who benefit
most. Start and stopping rules for ERT in Pompe disease
have always been applied in the Netherlands and entail
that treatment should only be initiated in symptomatic
patients and treatment should be discontinued if pa-
tients do not show response to treatment. As more evi-
dence becomes available, these start and stopping rules
can be improved over time. European recommendations
on these start and stopping rules have recently been
published by the European Pompe Consortium [8, 36].
Whether the cost-effectiveness criterion should play a
role in the reimbursement of orphan drugs has been
debated, both in scientific literature [37–39] as well as in
a broader societal setting [40]. Cost-effectiveness is used
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to maximize health under a given budget constraint. The
cost-effectiveness threshold quantifies the societal will-
ingness to pay for one unit of health gain. In the
Netherlands, cost-effectiveness thresholds are used to
guide discussions on cost-effectiveness, but these thresh-
olds are not a conclusive reimbursement criterion. The
Dutch threshold is dependent on the severity of a
disease: for diseases with a severity between 0.1 and 0.4
the threshold is €20,000/QALY; for diseases with a
severity between 0.41 and 0.7 the threshold is €50,000/
QALY; and for diseases with a severity between 0.71 and
1 the threshold is €80,000/QALY [41]. The use of a
higher cost-effectiveness threshold for orphan drugs has
been suggested [42]. The basic questions are whether a
societal preference for rarity and inherited diseases exists
and how much society wants to avoid denying access to
treatment for patients with these diseases. Several
positive reimbursement decisions for orphan drugs and
the existence of programmes designed specifically to give
patients with rare diseases access to treatment in various
countries (e.g. the Life Savings Drug Program in
Australia; the Scottish Rare Conditions Medicines Fund)
imply that policy makers believe this preference to exist.
Empirical evidence on societal preferences for rarity is
limited and mixed [43–46]. Further evidence is needed
on societal preferences in other countries, including the
Netherlands, and in what way policymakers incorporate
these views in decision making. Theoretically, the cost-
effectiveness threshold should reflect the opportunity
costs of healthcare spending. When the ICER of an
intervention is smaller than the threshold, the health
gains of a new intervention exceed the health effects of
the interventions that are displaced elsewhere in the
healthcare system to compensate for the additional costs
of the new technology. Empirical data on the value of
displacement costs in the Netherlands are not yet avail-
able. Other criteria also seem to play a role in
reimbursement decisions. A systematic literature review
found nine other criteria that were used in decision
making on orphan drugs: uniqueness of the indication,
prevalence of the disease, disease severity, advancement
of technology, complexity of manufacturing, unmet
medical need, scientific evidence on effectiveness, drug
safety, and budget impact [47]. In addition to these cri-
teria, other studies identified the availability of alterna-
tive treatments, social impact of the disease and
treatment, whether follow-up research will be per-
formed, and whether the drug is disease modifying or
not as criteria that can be important in reimbursement
decisions on orphan drugs [48, 49]. From the perspective
of the physicians and the patients, the fact that Pompe
disease is still the first and only proven treatable inherit-
able skeletal muscle disorder may also play a role. The
knowledge obtained may be used for the better
understanding of similar diseases and in the develop-
ment of next generation and other innovative therapies.
Conclusions
This model-based cost-effectiveness study has shown the
significant benefits of ERT in adult Pompe disease in
terms of survival and QALYs over a life-time horizon.
The study in this rare orphan disease could be per-
formed due to the start of prospective collection of data
4 years before ERT was registered. It has also shown that
the high price of ERT for this ultra-rare disease results
in a cost-effectiveness ratio of ERT that by far does not
meet the conventional threshold values.
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